Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
ConclusionsKidney function impairment increased the AUC of roxadustat and its metabolites. TheCmax andt1/2 of roxadustat were comparable among groups. Roxadustat and its metabolites were not cleared by HD/HDF.Clinical Trials Registration Number: NCT02965040.
Source: European Journal of Drug Metabolism and Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Chronic Kidney Disease | Clinical Trials | Dialysis | Drugs & Pharmacology | Hemodiafiltration | Hemodialysis | Peritoneal Dialysis | Study | Urology & Nephrology